Collaborations in Quality Assessments and Inspections
July 1, 2024
In a new development for global pharmaceutical regulation, the FDA and the European
In a new development for global pharmaceutical regulation, the FDA and the European
We enjoyed our very own Teresa Gorecki, Practice Lead at Compliance Architects, speaking
There are no FDA regulations governing writing quality or clarity. FDA Investigators will never
In today’s pharmaceutical manufacturing landscape, trust is paramount. Patients rely on drug manufacturers’
In the dynamic landscape of biopharmaceuticals, ensuring the potency of cellular therapy or
The FDA and other global regulators rely on data reviews during inspections to determine whether a
Cell and gene therapies represent a new medical frontier, offering hope for treating
In the realm of quality and compliance within pharmaceuticals, biopharmaceuticals, and combination products,
The highly anticipated FDA Decision on the Harmonization of the Medical Device Quality
Attention life science quality and compliance professionals. Mark your calendars for this Thursday,
© 2009-2025 Compliance Architects Holdings LLC – used by permission. All copyrights, trademarks and other intellectual property are the property of Compliance Architects Holdings LLC and are used by permission.
